Research tests cost-effective approach to early-cancer detection from cell-free DNA in blood samples
Exposure to air pollution worsens COVID-19 outcomes, even among the fully vaccinated
29 September 2022New study finds care home residents benefit from robot pets
29 September 2022Research tests cost-effective approach to early-cancer detection from cell-free DNA in blood samples
Early detection remains key to successfully treating many cancers, and early detection via cell-free DNA (cfDNA) circulating in the bloodstream—the so-called “liquid biopsy”—has become a research focal point. But using this method to detect cancer at its early stages has been challenging due to low tumor concentrations in DNA blood fragments and the genetic diversity of cancer.
